Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GlaxoSmithKline sues Lupin over Combivir patent

This article was originally published in Scrip

Executive Summary

GlaxoSmithKlinehas filed a suit against Lupinin the US district court of Delaware claiming infringement of its patent for the anti-AIDS drug Combivir (lamivudine 150mg and zidovudine 300mg). The US FDA had in September 1997 granted approval to GSK to sell Combivir tablets. GSK claims that it will be irreparably harmed by Lupin's infringing activities unless enjoined by court. It has claimed monetary relief should Lupin manufacture and sell the product in the US or import the product before the expiry of the patent. Lupin's managing director, Dr Kamal Sharma, said that Lupin had filed a paragraph IV certification for GSK's patent for Combivir and is confident of the merit of its case. Lupin said that it is committed to bringing down healthcare costs worldwide through world-class quality generics and play a critical role in enhancing access to medicine for a larger patient population.

You may also be interested in...

India Regulatory Diary: Marketers Co-Accountable For Lapses In Manufacturing Quality

New rules in India specify that a marketer of a drug will share the onus for quality and compliance along with the manufacturer. Enhanced punishment for misleading advertisements for a range of illnesses is also proposed, while calls for a statute to regulate pharma's marketing practices grow louder.

Ex-Janssen India Chief To Lead PE-Controlled Bharat Serums

Former managing director of Janssen India to helm Bharat Serums and Vaccines following the firm’s acquisition by private equity firm Advent International.

Asia Deal Watch: Strides Obtains 18 US ANDAs From Pharmaceutics

Deal news from Strides Pharma, Pharmaceutics Intl., Cipla, Wanbury, AstraZeneca, Syntekabio, Arctoris, Mundipharma, Samsung Bioepis…


Related Companies




Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts